Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide

被引：94

作者：

Chedore, Pamela ^{[1
]}

Bertucci, Lina ^{[1
]}

Wolfe, Joyce ^{[2
]}

Sharma, Meenu ^{[2
]}

Jamieson, Frances ^{[1
]}

机构：

[1] Ontario Agcy Hlth Protect & Promot, Publ Hlth Lab, Toronto, ON M9P 3T1, Canada

[2] Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, Natl Reference Ctr Mycobacteriol, Winnipeg, MB, Canada

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2010年 / 48卷 / 01期

关键词：

PNCA; MUTATIONS;

D O I：

10.1128/JCM.01775-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

During susceptibility testing of 743 isolates of Mycobacterium tuberculosis to pyrazinamide (PZA) using the Bactec 960 system, 57 (7.7%) isolates showed PZA resistance. Repeat testing of resistant isolates with the Bactec 460 reference method confirmed 33 (4.4%) of these isolates as resistant, and 24 (3.2%) were susceptible. Erroneous results for resistance with the Bactec 960 were confirmed by testing the 24 discordant isolates for pyrazinamidase and mutations in the pncA gene.

引用

页码：300 / 301

页数：2

共 15 条

[1] Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA):: compared with the results of pyrazinamidase assay and Kyokuto PZA test [J].

Aono, A ;

Hirano, K ;

Hamasaki, S ;

Abe, C .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (04) :347-352

[2]

Becton Dickinson and Company, 1999, BACT MGIT 960 SYST U

[3]

CLARK RB, 2009, CUMITECH 31A VERIFIC, P14

[4]

*CLSI NCCLS, 2003, M24A CLSINCCLS, V23

[5] Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis [J].

Davies, AP ;

Billington, OJ ;

McHugh, TD ;

Mitchison, DA ;

Gillespie, SH .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) :3686-3688

[6] Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide:: comparison with the radiometric Bactec 460TB system [J].

Kontos, F ;

Nicolaou, S ;

Kostopoulos, C ;

Gitti, Z ;

Petinaki, E ;

Maniati, M ;

Anagnostou, S ;

Raftopoulou, A ;

Papageorgiou, P ;

Scrioubellou, A ;

Tselentis, I ;

Maniatis, AN .

JOURNAL OF MICROBIOLOGICAL METHODS, 2003, 55 (01) :331-333

[7] Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis [J].

Mestdagh, M ;

Fonteyne, PA ;

Realini, L ;

Rossau, R ;

Jannes, G ;

Mijs, W ;

De Smet, KAL ;

Portaels, F ;

Van den Eeckhout, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2317-2319

[8] Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis [J].

Morlock, GP ;

Crawford, JT ;

Butler, WR ;

Brim, SE ;

Sikes, D ;

Mazurek, GH ;

Woodley, CL ;

Cooksey, RC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2291-2295

[9] Laboratory diagnostic aspects of drug resistant tuberculosis [J].

Parsons, LM ;

Somoskövi, A ;

Urbanczik, R ;

Salfinger, M .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :2086-2105

[10] Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system [J].

Pfyffer, GE ;

Palicova, F ;

Rüsch-Gerdes, S .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (05) :1670-1674

← 1 2 →